Top Ways to Trade a Potential $100 Billion Obesity Treatment Boom – 4/2

Biotech is one of the hottest sectors on the market.

In fact, a big part of the reason why is obesity.

Since the start of the year, Eli Lilly (LLY) jumped from about $560 to $778. Part of that was thanks to sales of its obesity drug, Zepbound which saw $175.8 million in its first month out. Even better, Eli Lilly is seeing positive results in Phase 2 drug trials for patients with NASH, or nonalcoholic steatohepatitis, which impacts about 115 million patients all around the world.

Or, look at Novo Nordisk (NVO), which jumped from about $95 to a high of $135 thanks to Wegovy obesity drug sales, too. The company even forecast another year of double-digit sales growth for this year, and expects to boost U.S. supplies of Wegovy again this year.


Wall Street Stockpicker Names #1 AI Stock of 2024

The greatest quantitative mind on Wall Street just revealed his #1 A.I. pick, 100% free.

Click here to learn more…


There’s also Viking Therapeutics (VKTX).

The company is seeing good success with its GLP-1 obesity drug trials. It already reported that its Phase 2 VENTURE trial successfully achieved is primary endpoint and all secondary endpoints. It also said patients receiving VK-2735 demonstrated weight loss after 13 weeks, rating up to 14.7% from baseline weight.

It’s also about to start Phase 2 trials of its once-a-day weight loss pill. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days, as noted by CNBC.

This is just the start, though.


The 10-Minute Trader [Just One Easy Trade]

Hugh Grossman introduces a unique “day trading” system that involves just one simple option trade taking 10 minutes a day, unlike traditional day trading involving hours glued to the screen.

This fast and easy system requires opening an email, typing in the option symbol, setting the profit target, and walking away for the rest of the day. Only 87 new option traders today get to see how this new way to trade works, so better hurry.

Click here for the 10-minute simple options trading day.


We also have to consider the obesity drug market could explode to $100 billion by 2030, says Goldman Sachs. “The obesity market is still in its early stages,” Chris Shibutani, senior biopharmaceuticals analyst in Goldman Sachs Research, writes in the team’s report, noting there are uncertainties around the assumptions in the team’s model. The $100 billion forecast is “relatively sensitive to minor tweaks to underlying drivers.”

In addition, according to the World Health Organization, obesity has tripled since 1975.  More than 1.9 billion adults were overweight as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016, as well.  

At the rate we’re going, obesity will be the downfall for millions.

However, if millions of people can take a pill or get a shot to help lose weight, it could create an unbelievable multi, multi-billion-dollar opportunity.


Potential Danger For Retirement Accounts Tied to Stocks

Market Corrections can eat into the value of your account. This FREE Guide can help you discover ways that may assist in keeping more of your money where you want it.


Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.